Drug Innovation

Commentary

A Real and Present Threat to Alzheimer’s Patients

It’s a quintessential government outcome. A program intended to increase access to promising medical innovations is actually preventing Medicare beneficiaries from receiving FDA-approved treatments. Medicare’s “coverage with evidence development” (CED) was never authorized by Congress. Instead, the Centers for Medicare & Medicaid Services created the program in 2005 by leveraging ...
Blog

The 340B Discounts Hospitals Receive Will Often Exceed Total Drug Prices in Europe

Table 1: PBM Fees and Rebates Can Exceed International Prescription Medicine Prices by As Much As 900% I previously highlighted how estimated rebates and fees PBMs receive for 10 commonly used brand medicines far exceed the total prices of those medicines in eight OECD countries (see Table 1). For example, ...
Drug Importation

Listen to Sally Pipes on “Free the Economy” podcast

Listen to PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally C. Pipes discuss her new book The World’s Medicine Chest (Encounter Books) on the Free the Economy podcast from the Competitive Enterprise Institute. Click here to listen
Blog

Read the latest on the push for drug price controls

To Improve Drug Affordability Congress Should Fix the Payment System

Demanding that drug prices in the U.S. equal overseas prices is akin to demanding that the price of all expensive handbags should equal the prices for the knockoffs that people purchase from street vendors. Of course knockoff bags are cheaper. They violate the intellectual property rights of the bag’s maker, ...
Drug Importation

Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”

Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Commentary

Banning mRNA vaccines would stop emerging cancer treatments

Several states have effectively declared war on medical progress. Lawmakers in Iowa, Montana, Idaho, Texas and Kentucky introduced bills that would ban or restrict vaccines that use messenger RNA, or mRNA, technology — despite its immense potential for treating and even preventing some of the most vexing diseases known to ...
Commentary

Drug company profits don’t threaten lives; price controls do

More than 4 in 5 Americans blame the pharmaceutical industry’s profits for the high prices of prescription drugs. It’s little wonder, then, that roughly the same share supports placing price controls on prescription drugs through Medicare. The logic is straight out of Robin Hood. Our leaders should take from the ...
Commentary

Deregulation Is The Pathway To Greater Pharmaceutical Innovation

Surveys confirm that most Americans recognize the value of prescription drugs. But the same surveys also show that Americans are worried that they will be unable to afford needed medicines. These conflicting feelings exemplify the inherent tension when it comes to prescription drugs – how do we incentivize innovation to ...
Blog

Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field

The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Drug Importation

Sally Pipes – The World’s Medicine Chest

This week, we present a special presentation of our recent webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores ...
Commentary

A Real and Present Threat to Alzheimer’s Patients

It’s a quintessential government outcome. A program intended to increase access to promising medical innovations is actually preventing Medicare beneficiaries from receiving FDA-approved treatments. Medicare’s “coverage with evidence development” (CED) was never authorized by Congress. Instead, the Centers for Medicare & Medicaid Services created the program in 2005 by leveraging ...
Blog

The 340B Discounts Hospitals Receive Will Often Exceed Total Drug Prices in Europe

Table 1: PBM Fees and Rebates Can Exceed International Prescription Medicine Prices by As Much As 900% I previously highlighted how estimated rebates and fees PBMs receive for 10 commonly used brand medicines far exceed the total prices of those medicines in eight OECD countries (see Table 1). For example, ...
Drug Importation

Listen to Sally Pipes on “Free the Economy” podcast

Listen to PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally C. Pipes discuss her new book The World’s Medicine Chest (Encounter Books) on the Free the Economy podcast from the Competitive Enterprise Institute. Click here to listen
Blog

Read the latest on the push for drug price controls

To Improve Drug Affordability Congress Should Fix the Payment System

Demanding that drug prices in the U.S. equal overseas prices is akin to demanding that the price of all expensive handbags should equal the prices for the knockoffs that people purchase from street vendors. Of course knockoff bags are cheaper. They violate the intellectual property rights of the bag’s maker, ...
Drug Importation

Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”

Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Commentary

Banning mRNA vaccines would stop emerging cancer treatments

Several states have effectively declared war on medical progress. Lawmakers in Iowa, Montana, Idaho, Texas and Kentucky introduced bills that would ban or restrict vaccines that use messenger RNA, or mRNA, technology — despite its immense potential for treating and even preventing some of the most vexing diseases known to ...
Commentary

Drug company profits don’t threaten lives; price controls do

More than 4 in 5 Americans blame the pharmaceutical industry’s profits for the high prices of prescription drugs. It’s little wonder, then, that roughly the same share supports placing price controls on prescription drugs through Medicare. The logic is straight out of Robin Hood. Our leaders should take from the ...
Commentary

Deregulation Is The Pathway To Greater Pharmaceutical Innovation

Surveys confirm that most Americans recognize the value of prescription drugs. But the same surveys also show that Americans are worried that they will be unable to afford needed medicines. These conflicting feelings exemplify the inherent tension when it comes to prescription drugs – how do we incentivize innovation to ...
Blog

Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field

The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Drug Importation

Sally Pipes – The World’s Medicine Chest

This week, we present a special presentation of our recent webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores ...
Scroll to Top